Pfizer (NYSE:PFE) Trading Up 0.6% – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s share price was up 0.6% during mid-day trading on Wednesday . The company traded as high as $24.69 and last traded at $24.70. Approximately 8,969,546 shares changed hands during trading, a decline of 77% from the average daily volume of 39,089,397 shares. The stock had previously closed at $24.54.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PFE shares. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

The business has a 50 day moving average price of $25.93 and a 200 day moving average price of $26.81. The stock has a market cap of $137.79 billion, a P/E ratio of 17.23, a PEG ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.